Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401044 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
A Phase 1 study of Thyroid Eye Disease, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT06401044 is a Phase 1 study of Thyroid Eye Disease that is actively recruiting participants, run by Amgen. The registered enrollment target is 88 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06401044, a Phase 1 study of Thyroid Eye Disease, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AMG 732
Study Locations (20)
Other
- Centre Hospitalier Universitaire de Nantes - Hopital Nord Laennec - Nantes
- Hopital Pitie-Salpetriere - Paris
- Universitaetsklinikum Essen - Essen
- Dc-Med Spolka z Ograniczona Odpowiedzialnoscia Spolka Komandytowa - Swidnica
- Eb Group Spolka z ograniczona odpowiedzialnoscia - Warsaw
- Singapore National Eye Centre - Singapore
- Hospital Universitario Ramon y Cajal - Madrid
Florida
- Levenson Eye Associates - Jacksonville
- Ilumina Medical Research - Kissimmee
- Sarasota Retina Institute - Sarasota
New South Wales
- Macquarie University - North Ryde
- North Shore Private Hospital - St Leonards
Arkansas
- Applied Research Center of Arkansas - Little Rock
Illinois
- Vision Medical Research, Inc. - Orland Park
Nevada
- Ppd Las Vegas Research Unit - Las Vegas
Pennsylvania
- Erie Retina Research - Erie
Texas
- Consano Clinical Research, LLC - Shavano Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401044
The ClinicalTrials.gov registry entry for NCT06401044 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (13% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06401044 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06401044 about?
NCT06401044 is a clinical study titled "A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease". The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
What is the current status of trial NCT06401044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2024-05-30. Estimated completion is 2027-08-13.
What conditions does trial NCT06401044 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06401044?
The interventions under investigation include: Placebo (OTHER), AMG 732 (DRUG).
Who is sponsoring clinical trial NCT06401044?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401044 being conducted?
This trial has 20 study locations across Arkansas, Florida, Illinois, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.